Primary Adrenal Diffuse Large B-cell Lymphoma: A Mini Review

1Rajeev Parameswaran, 2Dedrick Kok Hang Chan, 3Poon Li Mei Michelle, 4Shi Wang

ABSTRACT

Background: Primary adrenal diffuse large B-cell lymphoma are aggressive high grade lymphomas affecting elderly gentlemen and mostly present with bilateral enlarged adrenal masses associated with B symptoms, adrenal insufficiency and elevated lactate dehydrogenase. When imaged with CT or ultrasound, these lesions usually appear as heterogeneous complex large masses with low density. They appear metabolically active on PET scan. Confirmatory diagnosis is established by image guided biopsy or surgical excision. Treatment is usually with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or CHOP like regimes. Surgery has very limited role, if any in the management of this condition. The prognosis is generally poor with only about a third of patients achieving partial or complete remission following treatment. A concise review of the literature (PubMed database; 1990–2014) on the clinical management of primary adrenal lymphoma along with a case example is discussed.

Keywords: Adrenal, Adrenal tumor, Lymphoma.

How to cite this article: Parameswaran R, Chan DKH, Michelle PLM, Wang S. Primary Adrenal Diffuse Large B-cell Lymphoma: A Mini Review. World J Endoc Surg 2015;7(3):65-68.

Source of support: Nil

Conflict of interest: None

INTRODUCTION

Primary adrenal tumors are most commonly adenomas or carcinomas.1 Primary adrenal lymphomas (PALs) are rare, and represent only about 3% of primary extranodal lymphomas.2 Primary adrenal lymphomas is usually a non-Hodgkin lymphoma, with diffuse large B-cell lymphoma being the most common subtype, and seen in about 70% of patients.3–6 The characteristic clinical features also include a high incidence of bilateral7,8 and a low incidence of extra-adrenal disease at diagnosis. Recognizing this rare condition is important as the treatment varies greatly between carcinoma and lymphoma, with the former managed predominantly with surgery, whilst the latter relying on chemotherapeutic regimes. Here we illustrate a case and briefly review the incidence, clinical features, investigations and management of this condition. Articles published in English from 1990 to 2014 were identified by searching PubMed using the search terms ‘primary’, ‘adrenal’, ‘lymphoma’, ‘treatment’ and ‘prognosis’ and used for review.

CASE REPORT

A 58-year-old Malay gentleman without significant comorbid medical conditions presented with a 1 month history of low grade fever and backache following a recent trip to Morocco. There was no associated history of night sweats, loss of weight or appetite, and no family history of malignancy. Initial investigations for an infectious etiology in light of his recent travel history were negative. A computed tomography (CT) scan of the abdomen and pelvis was performed which showed large bilateral adrenal tumors. The left adrenal gland measures 8.0 cm in maximum dimension, while the right adrenal gland measures 4.0 cm in maximum dimension (Fig. 1). There was no other organ involvement.

Screening for functional assessment of the adrenal gland was normal for cortisol, renin aldosterone ratio (RAA) and urinary catecholamines. Positron emission tomography/computed tomography (PET/CT) to further characterize the presence of extra-adrenal disease showed no other F-18 Fluorodeoxyglucose (FDG) avid lesions apart from the adrenals (Fig. 2). With a clinical suspicion of primary adrenal lymphoma, a percutaneous CT guided biopsy of the adrenal lesion was performed.

Histological findings showed sheets of medium to large neoplastic lymphoid cells with vesicular nuclei and single to multiple nucleoli (Figs 3A and B). There...
was conspicuous mitotic activity and apoptotic activity. Immunohistochemical stains were also performed. The neoplastic lymphoid cells expressed LCA, CD20 (Fig. 3C), CD79A, BCL6, MUM1, BCL2 and CMYC and were negative for CD10 and Cyclin D1. The Ki-67 proliferative index was up to 90% (Fig. 3D). A diagnosis of diffuse large B-cell lymphoma (nongerminal center-like) was made. The patient was treated with R-CHOP therapy.

Fig. 1: Computed tomography scan showing large bilateral adrenal lesions. The left adrenal measured 8.0 cm, and the right adrenal measured 4.0 cm; axial CT imaging showing bilateral, bulky adrenal masses (arrows point to location of tumors)

Fig. 2: Positron emission tomography/computed tomography showing no other locations of significant FDG-avid lesions apart from the adrenals, PET-CT image showing left adrenal FDG avid tumor (arrow pointing to tumor)

Figs 3A to D: The adrenal tumor is composed of sheets of medium to large sized neoplastic lymphoid cells with vesicular nuclei and single to multiple nucleoli. H&E Original magnifications 200× (A) and 400× (B), the neoplastic lymphoid cells are positive for CD20; Original magnification 400× (C) the neoplastic lymphoid cells have a high Ki-67 proliferative index of up to 90%; original magnification 400× (D); histological slides showing presence of DLBCL
DISCUSSION

Primary adrenal lymphomas are rare, but remain a diagnostic possibility in the evaluation of adrenal masses (Table 1). The diagnosis of a patient with primary adrenal lymphoma can be challenging because symptoms are non-specific, and only 50% of patients have concomitant adrenal insufficiency, which occurs when there is at least 90% destruction of adrenal parenchyma. Other features which can point to the diagnosis of primary adrenal lymphoma include a male predominance, as well as the presence of bilateral disease. Bilateral adrenocortical carcinoma occurs in only 10% of patients, whereas lymphoma is more commonly bilateral in more than 50% of cases. There is lack of a uniform consensus on the definition of primary adrenal lymphoma in the past. However, recently there have been efforts to define this disease entity. Primary adrenal lymphoma is defined when both of the following conditions are present: a. There is no prior history of lymphoma elsewhere; b. If lymph nodes or other organs are involved, adrenal lesions are unequivocally dominant.

The incidence of primary adrenal lymphoma has been increasing over the last few decades, most likely due to improved diagnostic imaging modalities. Men appear to be affected more than women and adrenal involvement is bilateral in more than 70% of cases. The most common symptoms are fever, pain and associated B-symptoms, and seen with bilateral lesions in comparison to unilateral lesions. The incidence of adrenal insufficiency is seen in patients with more than 90% of gland destruction and more commonly in the presence of bilateral disease. Diagnostic modalities include imaging with ultrasoundography (US), CT, magnetic resonance imaging (MRI) and functional imaging, such as gallium 67 scintigraphy imaging or positron emission tomography scans. On MRI imaging, the adrenal lesions are characterized by low signal intensity on T1-weighted images, and heterogeneous high signal intensity on T2-weighted images. Histologic diagnosis is confirmative, but requires functional assessment prior to tissue biopsy (Tables 2 and 3). The predominant type of primary adrenal lymphoma in more than 70% of cases is diffuse large B-cell lymphoma (DLBCL), with a nongerminatal center B-cell phenotype. Most cases of primary adrenal DLBCL have BCL6 gene rearrangement and is associated with a poor prognosis.

Numerous treatment regimens for the management of primary adrenal lymphoma have been proposed, however owing to the rarity of this condition, no comparisons have been made between the various treatment modalities. These modalities include bilateral adrenalectomy, chemotherapy, radiotherapy, and a combination of these. The role of bilateral adrenalectomy remains controversial and has been associated with poor prognosis. It is therefore important to establish a diagnosis of lymphoma via percutaneous techniques as opposed to following resection of the tumor as this subjects the patient to unnecessary surgical morbidity.

Chemotherapy remains the mainstay of treatment. CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) which is the most commonly used regimen for lymphomas has been used for the treatment of primary adrenal lymphoma. The addition of rituximab to the CHOP regimen in patients with primary adrenal lymphoma was studied in a retrospective review by Kim et al and showed encouraging improvements in overall survival as well as complete remission rates. Two years overall survival rate was 68.3%, with complete remission achieved in 54.8% of patients. In particular, the impact on outcomes of rituximab therapy has shown to be greatest in the elderly. The study also concluded that complete remission was associated with improved overall survival rates. In contrast, surgery and radiotherapy have not been shown to have survival benefit for patients.
**CONCLUSION**

Establishing the correct diagnosis of adrenal lymphoma is essential in the management of the patient. Though rare, this condition must be suspected when large bulky and bilateral adrenal tumors are found. The treatment for adrenal lymphoma is nonsurgical, and obtaining a diagnosis precludes the patient from potentially debilitating major surgery. The prognosis of the condition is generally poor.

**REFERENCES**


